


OvRSeq Analysis Report for TCGA-29-1784

2023-11-28


The vulnerability map indicate based on BRCAness probability and CYT to C1QA ratio (C2C) indications with a high vulnerability (score) for response to combination immunotherapy with PARPi and immune checkpoint inhibitors.



Patient values

Feature	Value
BRCAness Status	1 (0.932)
Infiltration Status	Infiltrated
Molecular Subtypes	IMR consensus
BRCAness immunotype	other
Vulnerability Score	2.822
Immuno Phenoscore	4
CYT to C1QA Ratio (C2C)	0.003
Angiogenesis Score	

Molecular markers and TCGA-OV Reference Values. Marker gene expression levels and respective Q1 and Q3 levels (interquartile range) from the TCGA cohort.



Feature	Patient Value	TCGA IQR
CD274	1.9	1.325 (0.874-1.859)
GZMB	3.65	2.548 (1.625-3.511)
PRF1	2.356	1.731 (1.152-2.505)
C1QA	8.712	7.35 (6.411-8.18)
CD8A	3.379	1.904 (1.168-2.648)
IDO1	5.259	4.161 (2.802-5.446)
FOXP3	2.253	1.938 (1.318-2.521)
TREM2	6.817	4.83 (3.761-5.638)
STAT1	7.111	7.015 (6.207-7.551)
HLA-DRA	9.24	7.262 (6.298-8.001)
CXCL10	8.554	6.379 (5.032-7.539)

